Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

(2014) Florian Cabillic et al.   Journal of Thoracic Oncology

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

(2013) Neal I. Lindeman et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases

(2013) Jennifer M. Boland et al.   Journal of Thoracic Oncology

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

(2012) Hisashi Tanaka et al.   BMC CANCER

EGFRandK-rasmutations in cytologic samples from fine-needle aspirates in NSCLC patients: Table 1–

(2012) Paola Ulivi et al.   EUROPEAN RESPIRATORY JOURNAL

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib

(2011) Sanjay Popat et al.   Journal of Thoracic Oncology

Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes

(2011) M. D. Lozano et al.   ONCOLOGIST

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation

(2010) Yao-Wen Kuo et al.   Journal of Thoracic Oncology

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

(2010) M. Tiseo et al.   LUNG CANCER

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

(2010) Xuchao Zhang et al.   Molecular Cancer

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH